Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.

BMC Psychiatry · 2021 · PMC8547110 · PMID 34696742

Europe PMC DOI

hedged sentence

0.4750

closest p · 9.5× alpha

0.4750

boldest claim

The sentences

did not reach statistical significancep = 0.475not close (p > 0.1)

The improvement in the esketamine groups compared with the placebo group did not reach statistical significance (1-sided p = 0.475, p = 0.504, and p = 0.482, respectively) (Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.